Four Outcomes to Look for in an Eczema Trial: Understanding the HOME Framework

Doctor’s Notes · Eczema Research · November 2026

A headline saying an eczema treatment worked may leave out what improved. Was it itch, visible signs, daily-life impact or longer-term control? The Harmonising Outcome Measures for Eczema initiative developed a framework to make trial reporting more consistent and comparisons more informative.

Four domains prevent one result from standing for everything

The 2022 HOME core-outcome report recommended four domains for atopic dermatitis trials: symptoms, clinical signs, quality of life and long-term control. It specified suitable instruments for each. This is a research reporting framework, not a rule that a person must complete every questionnaire at every visit. A clinical-sign result cannot automatically be substituted for an itch or quality-of-life result.

Read the endpoint before the percentage

When a study reports a responder rate, identify the instrument, threshold and time point. A percentage reduction in a skin score and the percentage of participants becoming clear are different outcomes. Check whether the headline concerns the primary endpoint, a secondary outcome or a subgroup. The framework can make those distinctions easier to spot.

Keep age and duration visible

A trial's quality-of-life instrument should match its population, and a short study cannot alone establish long-term control. Look for follow-up, comparator and missing data as well as the score. Comparing two separate trials requires more than placing their largest percentages side by side.

Use the framework at a care review

Explain which outcome matters most in your current week: sleep interruption, visible inflammation, a task you cannot do comfortably or repeated flares. The care team can choose appropriate assessment and treatment. A moisturizer's hydration study should not be represented as an eczema trial simply because both use a numerical result.

Related care questions include what is scorad? understanding an eczema severity score and what does easi-75 mean in an eczema study?. Keep each question connected to its own symptoms, exposure and evidence.

Dr. Arsy #003 in this discussion

Dr. Arsy #003 provides cosmetic hydration and moisture-barrier support. HOME does not certify the cream or convert cosmetic testing into evidence of eczema treatment. Claims for #003 must stay tied to the actual product evidence and directions; the framework concerns how eczema trials should report outcomes.

Measurement choices also shape how we read the six-question ADCT and a pediatric eczema-app trial.

Sources and further reading

1. Primary research record, PubMed

Dr. Arsy Editorial Team. General education, not independent medical review. Discuss diagnosis and treatment with a qualified clinician. #003 is cosmetic moisture care, not an eczema medicine. Image is an AI-generated scene based on the actual product jar. PubMed indexing does not imply NIH endorsement.